COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre study

Abstract

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

COVID-19 and pulmonary alveolar proteinosis: an unusual combination

“…However, there are few data regarding COVID-19 and rare lung diseases. Recent series 5 , 6 in patients with lymphangioleiomyomatosis and PAP showed increased rates of hospitalization in these populations (approximately one-third of these patients in both studies).…”

“…Few studies described the combination of PAP and COVID-19, and none, to the best of our knowledge, described the performance of WLL in patients with both diseases. A recent European multicenter study 6 described the incidence and outcomes of patients with PAP coinfected with COVID-19. Despite having similar COVID-19 rates when compared with the general population (about 15%), patients with PAP had a higher risk of hospitalization and death (35% required hospitalization, almost 50% of those in the ICU, and, of these, 27% died or underwent lung transplantation).…”

“…No entanto, existem poucos dados sobre COVID-19 e doenças pulmonares raras. Séries recentes (5,6) envolvendo pacientes com linfangioleiomiomatose e PAP mostraram taxas maiores de hospitalização nessas populações (aproximadamente um terço dos pacientes em ambos os estudos).…”

“…Poucos estudos descreveram a combinação de PAP e COVID-19 e nenhum, até onde sabemos, descreveu o desempenho da LPT em pacientes com ambas as doenças. Um recente estudo multicêntrico europeu (6) descreveu a incidência e os resultados de pacientes com PAP coinfectados com COVID-19. Apesar de apresentarem taxas semelhantes de COVID-19 quando comparados com a população geral (cerca de 15%), os pacientes com PAP apresentavam maior risco de internação e morte (35% necessitaram de internação, quase 50% desses na UTI e, destes, 27% morreram ou foram submetidos a transplante de pulmão).…”

“…O tratamento com GM-CSF inalatório foi interrompido em todos os pacientes, e nenhum paciente foi submetido à LPT durante a internação. (6) Alguns estudos avaliaram a relação entre COVID-19 e o papel do GM-CSF. (7) Nos estágios iniciais da infecção, o papel do GM-CSF pode ser protetor, pois ajudaria a limitar…”